Sample | Title | Value | Rank |
GSM1256968 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 1 | 1099.17 | 97 |
GSM1256969 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 2 | 944.097 | 96 |
GSM1256970 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 3 | 1037.01 | 96 |
GSM1256971 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 4 | 1141.02 | 97 |
GSM1256988 | Yellow fever vaccinated NDs; Group 8: CD16pos, resident monocytes; ND 55 before YFV | 1428.72 | 97 |
GSM1256991 | Yellow fever vaccinated NDs; Group 9: CD16pos, resident monocytes; ND 55 seven days after YFV | 1516.68 | 98 |
GSM1256989 | Yellow fever vaccinated NDs; Group 8: CD16pos, resident monocytes; ND 56 before YFV | 1209.8 | 97 |
GSM1256992 | Yellow fever vaccinated NDs; Group 9: CD16pos, resident monocytes; ND 56 seven days after YFV | 1160.59 | 97 |
GSM1256990 | Yellow fever vaccinated NDs; Group 8: CD16pos, resident monocytes; ND 57 before YFV | 1244.32 | 97 |
GSM1256993 | Yellow fever vaccinated NDs; Group 9: CD16pos, resident monocytes; ND 57 seven days after YFV | 1313.13 | 97 |